|
|
Volumn 63, Issue 1, 2014, Pages 86-88
|
|
Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;
FLUORODEOXYGLUCOSE F 18;
PLACEBO;
RILAPLADIB;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
ADULT;
ARTERITIS;
ATHEROSCLEROTIC PLAQUE;
CARDIOVASCULAR RISK;
CONTROLLED STUDY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MECHANISM;
ENZYME ACTIVITY;
ENZYME INHIBITION;
FEMALE;
HUMAN;
IMAGE ANALYSIS;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
OUTCOME ASSESSMENT;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT DURATION;
ARTERY WALL;
ATHEROSCLEROSIS;
ENZYME INACTIVATION;
NUCLEAR MAGNETIC RESONANCE IMAGING;
TREATMENT RESPONSE;
1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;
ARTERITIS;
FEMALE;
FLUORODEOXYGLUCOSE F18;
FOLLOW-UP STUDIES;
HUMANS;
MALE;
MIDDLE AGED;
MULTICENTER STUDIES AS TOPIC;
PHOSPHOLIPASE A2 INHIBITORS;
POSITRON-EMISSION TOMOGRAPHY;
RADIOPHARMACEUTICALS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TIME FACTORS;
|
|
EID: 84891812420
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2013.07.050 Document Type: Letter |
|
Times cited : (77)
|
|
References (5)
|
